Nivolumab Plus FOLFOXIRI/Bevacizumab in First Line Chemotherapy of Advanced Colorectal Cancer RASm/BRAFm Patients
- Status
- COMPLETED
- Phase
- PHASE2
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC
- Status
- TERMINATED
- Phase
- PHASE2
Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG
- Status
- UNKNOWN
- Phase
- PHASE2
Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and Eribulin in HER2 Negative Metastatic Breast Cancer
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)
- Status
- TERMINATED
- Phase
- PHASE2
A Study of Nivolumab in Patients With Head and Neck Cancer.
- Status
- COMPLETED
- Phase
- N/A
SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab, BMS-986205, and Radiation Therapy With or Without Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Lenvatinib Plus Nivolumab Versus Lenvatinib for Advanced Hepatocellular Carcinoma With Hepatitis B Virus Infection
- Status
- WITHDRAWN
- Phase
- PHASE2/PHASE3
Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
A Study of the IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS
- Status
- WITHDRAWN
- Phase
- PHASE2
Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Nivolumab and Ipilimumab in People With Aggressive Pituitary Tumors
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
- Status
- COMPLETED
- Phase
- PHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3